Avacta Group PLC - Update on Adeptrix COVID-19 Diagnostic Test
Update on Clinical Validation of Adeptrix COVID-19 Diagnostic Test
Adeptrix's novel BAMS platform uses Affimer reagents to capture the virus and viral proteins from patient samples and combines this with the power of mass-spectrometry analysis to provide a highly sensitive and specific diagnostic test. Up to 1,000 nasopharyngeal swab or saliva samples per day can be analysed by a single technician using the BAMS assay, making it a very attractive high throughput technique for COVID-19 screening in the clinical setting.
Through the collaboration with the CONDOR scheme,
The work with the CONDOR programme will commence immediately to evaluate the test performance using real patient samples and will quickly progress to full clinical validation.
"I am delighted that the COVID-19 BAMS assay that we are developing with Adeptrix has been accepted into the CONDOR programme. This provides us with access to patient samples and partners in
We are confident that the BAMS assay will perform very well and potentially provide a new gold standard for laboratory reference testing for the COVID-19 infection. The BAMS assay runs on equipment that is already installed in most hospital clinical microbiology labs but is currently unused for COVID-19 testing. Therefore, with the potential for a single technician to analyse up to 1,000 samples a day, the BAMS assay will provide a significant boost to centralised hospital testing capacity around the world.
I am also very pleased that the CONDOR programme will support the clinical validation of the rapid saliva-based COVID-19 antigen test strip that we are developing with Cytiva. This, combined with other collaborations that we are putting in place, will provide us with access to a sufficient number of COVID-19 patient samples to allow us to quickly clinically validate the saliva rapid test.
I look forward to providing further updates in due course."
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).
For further information from
Tel: +44 (0) 844 414 0452
finnCap Ltd (Nominated Adviser and Joint Broker)
Tel: +44 (0) 207 220 0500
Yellow Jersey PR (Financial Media and IR)
Tel: +44 (0)203 829 5000
Tel: +44 (0)203 004 9512
Tel: +44 (0)7787 502 947
The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby,
The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of
By combining these two platforms the Company is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
This information is provided by RNS, the news service of the
Quick facts: Avacta Group PLC
Market Cap: £416.08 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE